Bär & Karrer advises Miele o the Establishment of a Joint Venture in the Fields of Infection Control and Life Science Miele and Metall Zug have reached an agreement outlining the establishment of a
In a resounding success, Lonza has secured its financial future by placing two tranches totaling CHF 400 million. The first tranche of CHF 185 million, featuring a 2.25% interest rate and maturing in 2028, was complemented by a second
In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
Memo Therapeutics, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF 25 million series C financing round led by Pureos Bioventures. Existing investors Swisscanto, Vesalius Biocapital, Adjuvant Capital, Verve Ventures, Schroders Capital, GF Group,
Memo Therapeutics, a late-stage biotech firm specializing in top-tier therapeutic antibodies, disclosed the successful conclusion of its CHF 25 million Series C funding round. This milestone was spearheaded by Pureos Bioventures, with strong participation from Memo
Walder Wyss has acted as legal counsel to SkyCell on the completion of a USD 57 million equity financing round at a USD 600 million valuation with M&G Investments, a global investment firm that invests
In a strategic move to enhance its presence in the healthcare sector, Swiss Post, under the legal guidance of Vischer, has acquired a stake in Steriparc, a promising joint venture specializing in the externalized handling
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
On October 4, 2023, Novartis successfully executed the spin-off of Sandoz by distributing Sandoz shares as a dividend-in-kind to Novartis shareholders and American Depositary Receipts (ADRs) holders. Sandoz shares are now listed on the SIX Swiss Exchange.
Homburger advised Tolremo therapeutics on the extension of its Series A financing round, bringing the total amount raised to USD 39 million (CHF 34.1 million). BioMedPartners led the round with participation from a new investor, Pierre Fabre
